NZ598883A - Crystalline forms of a parp inhibitor compound - Google Patents
Crystalline forms of a parp inhibitor compoundInfo
- Publication number
- NZ598883A NZ598883A NZ598883A NZ59888310A NZ598883A NZ 598883 A NZ598883 A NZ 598883A NZ 598883 A NZ598883 A NZ 598883A NZ 59888310 A NZ59888310 A NZ 59888310A NZ 598883 A NZ598883 A NZ 598883A
- Authority
- NZ
- New Zealand
- Prior art keywords
- theta
- degrees
- following peaks
- compound
- diffraction pattern
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23718009P | 2009-08-26 | 2009-08-26 | |
| PCT/US2010/046671 WO2011028580A1 (en) | 2009-08-26 | 2010-08-25 | Novel forms of a multicyclic compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ598883A true NZ598883A (en) | 2014-09-26 |
Family
ID=43033463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ598883A NZ598883A (en) | 2009-08-26 | 2010-08-25 | Crystalline forms of a parp inhibitor compound |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8633314B2 (enExample) |
| EP (1) | EP2470540B1 (enExample) |
| JP (3) | JP2013503173A (enExample) |
| KR (1) | KR20120092100A (enExample) |
| CN (1) | CN102482282A (enExample) |
| AU (1) | AU2010289746B2 (enExample) |
| BR (1) | BR112012004053A2 (enExample) |
| CA (1) | CA2772328C (enExample) |
| CL (1) | CL2012000478A1 (enExample) |
| DK (1) | DK2470540T3 (enExample) |
| EA (1) | EA020756B1 (enExample) |
| ES (1) | ES2572652T3 (enExample) |
| IL (1) | IL218132B (enExample) |
| MX (1) | MX2012002456A (enExample) |
| MY (1) | MY156873A (enExample) |
| NZ (1) | NZ598883A (enExample) |
| SG (1) | SG178852A1 (enExample) |
| UA (1) | UA110604C2 (enExample) |
| WO (1) | WO2011028580A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA020756B1 (ru) * | 2009-08-26 | 2015-01-30 | Сефалон, Инк. | Новые формы полициклического соединения |
| AU2015353549A1 (en) * | 2014-11-26 | 2017-06-01 | Cephalon, Inc. | Crystalline forms of PARP inhibitors |
| EP3478286B1 (en) | 2016-06-29 | 2024-01-03 | Tesaro, Inc. | Methods of treating ovarian cancer |
| MX2019011496A (es) | 2017-03-27 | 2020-01-23 | Tesaro Inc | Composiciones de niraparib. |
| BR112020006039A2 (pt) | 2017-09-26 | 2020-10-06 | Tesaro, Inc. | formulações de niraparibe |
| CN109632555B (zh) * | 2018-12-28 | 2021-07-27 | 上海新黄河制药有限公司 | 一种富马酸福莫特罗无定型含量的动态蒸汽吸附分析方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7122679B2 (en) * | 2000-05-09 | 2006-10-17 | Cephalon, Inc. | Multicyclic compounds and the use thereof |
| US20060276497A1 (en) | 2000-05-09 | 2006-12-07 | Cephalon, Inc. | Novel multicyclic compounds and the use thereof |
| CA2620052A1 (en) * | 2005-08-24 | 2007-03-01 | Inotek Pharmaceuticals Corporation | Indenoisoquinolinone analogs and methods of use thereof |
| CN101784268B (zh) * | 2006-11-20 | 2013-06-19 | 赛福伦公司 | 使用辐射敏化剂使肿瘤对辐射敏化的方法 |
| EA020756B1 (ru) * | 2009-08-26 | 2015-01-30 | Сефалон, Инк. | Новые формы полициклического соединения |
-
2010
- 2010-08-25 EA EA201270315A patent/EA020756B1/ru not_active IP Right Cessation
- 2010-08-25 CA CA2772328A patent/CA2772328C/en not_active Expired - Fee Related
- 2010-08-25 MX MX2012002456A patent/MX2012002456A/es active IP Right Grant
- 2010-08-25 MY MYPI2012000710A patent/MY156873A/en unknown
- 2010-08-25 EP EP10750210.6A patent/EP2470540B1/en active Active
- 2010-08-25 WO PCT/US2010/046671 patent/WO2011028580A1/en not_active Ceased
- 2010-08-25 CN CN2010800380284A patent/CN102482282A/zh active Pending
- 2010-08-25 NZ NZ598883A patent/NZ598883A/en not_active IP Right Cessation
- 2010-08-25 UA UAA201203501A patent/UA110604C2/uk unknown
- 2010-08-25 DK DK10750210.6T patent/DK2470540T3/en active
- 2010-08-25 AU AU2010289746A patent/AU2010289746B2/en not_active Ceased
- 2010-08-25 BR BR112012004053-7A patent/BR112012004053A2/pt not_active IP Right Cessation
- 2010-08-25 ES ES10750210.6T patent/ES2572652T3/es active Active
- 2010-08-25 SG SG2012012290A patent/SG178852A1/en unknown
- 2010-08-25 JP JP2012526945A patent/JP2013503173A/ja active Pending
- 2010-08-25 KR KR1020127007524A patent/KR20120092100A/ko not_active Ceased
-
2012
- 2012-02-15 IL IL218132A patent/IL218132B/en not_active IP Right Cessation
- 2012-02-24 CL CL2012000478A patent/CL2012000478A1/es unknown
- 2012-02-24 US US13/404,137 patent/US8633314B2/en not_active Expired - Fee Related
-
2015
- 2015-07-30 JP JP2015151114A patent/JP2016014029A/ja not_active Ceased
-
2017
- 2017-09-04 JP JP2017169876A patent/JP2018035158A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011028580A1 (en) | 2011-03-10 |
| EA201270315A1 (ru) | 2012-08-30 |
| CA2772328A1 (en) | 2011-03-10 |
| CL2012000478A1 (es) | 2012-11-05 |
| JP2016014029A (ja) | 2016-01-28 |
| MY156873A (en) | 2016-04-15 |
| CN102482282A (zh) | 2012-05-30 |
| UA110604C2 (uk) | 2016-01-25 |
| AU2010289746A1 (en) | 2012-04-12 |
| KR20120092100A (ko) | 2012-08-20 |
| ES2572652T3 (es) | 2016-06-01 |
| AU2010289746B2 (en) | 2016-07-07 |
| JP2013503173A (ja) | 2013-01-31 |
| DK2470540T3 (en) | 2016-08-01 |
| EP2470540A1 (en) | 2012-07-04 |
| EA020756B1 (ru) | 2015-01-30 |
| US20120214998A1 (en) | 2012-08-23 |
| US8633314B2 (en) | 2014-01-21 |
| BR112012004053A2 (pt) | 2020-12-08 |
| JP2018035158A (ja) | 2018-03-08 |
| EP2470540B1 (en) | 2016-04-20 |
| CA2772328C (en) | 2017-06-20 |
| MX2012002456A (es) | 2012-05-08 |
| IL218132A0 (en) | 2012-06-28 |
| HK1171750A1 (zh) | 2013-04-05 |
| IL218132B (en) | 2018-02-28 |
| SG178852A1 (en) | 2012-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ598883A (en) | Crystalline forms of a parp inhibitor compound | |
| WO2005113536A3 (en) | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands | |
| ZA200603861B (en) | Use of tricyclic compounds as glycine transport inhibitors | |
| CA2781661A1 (en) | Ship1 modulators and methods related thereto | |
| AU2022215237B2 (en) | Methods of preparing indolinobenzodiazepine derivatives | |
| CN101348483A (zh) | 菲并吲哚里西啶衍生物的制备 | |
| CN102249998A (zh) | 一种制备顺苯磺酸阿曲库铵的方法 | |
| WO2010030132A3 (ko) | 아데포비어 디피복실의 정제방법 | |
| CN103509025A (zh) | 一种盐酸依匹斯汀及其中间体的制备方法 | |
| CN105820111B (zh) | 一种催化剂的制备方法及其催化制备2,2-联吡啶的方法 | |
| Mohaqeq et al. | A flexible one-pot synthesis of 8, 10-dimethyl-12-aryl-9 H-naphto [1′, 2′: 5, 6] pyrano [2, 3-d] pyrimidine-9, 11-diones catalyzed by ZnO nanoparticles under solvent-free conditions | |
| WO2005090301B1 (en) | Crystalline form of atorvastatin hemi calcium | |
| Khan et al. | Synthesis of wilsoniamines A and B | |
| CN104341336A (zh) | 一种合成阿哌沙班重要中间体的新方法 | |
| CN105218433A (zh) | 一种琥珀酸多西拉敏新晶型及其制备方法和应用 | |
| CN103709039A (zh) | Cu-丝光沸石催化合成没食子酸甲(乙)酯的方法 | |
| Komatsuzaki et al. | An Anion Receptor Based on Poly-Substituted Cobalticinium Complexes. | |
| RU2772513C2 (ru) | Способы получения индолинобензодиазепиновых производных | |
| Huang et al. | An Improved Synthesis of 1, 4, 7-Triazacyclononanes (tacns) and 1, 4, 7, 10-Tetraazacyclododecanes (cyclens) | |
| CN106220625B (zh) | 一种盐酸哌仑西平关键中间体的合成方法 | |
| CN102993074A (zh) | 三环唑中间体邻甲基苯基硫脲合成工艺 | |
| AU2005321228A1 (en) | Arylpiperazine derivatives and use thereof as 5-HT1A receptor ligands | |
| CN105348167A (zh) | 奥拉西坦的精制方法 | |
| CN103848847A (zh) | 一种改进制备奥氮平及其晶型ii的方法 | |
| CN103435591A (zh) | 胡椒碱的化学合成方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 25 AUG 2017 BY WATERMARK PATENT AND TRADE MARKS ATTORNEYS Effective date: 20150108 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 AUG 2018 BY DENNEMEYER + CO Effective date: 20170726 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 AUG 2019 BY DENNEMEYER + CO Effective date: 20180802 |
|
| LAPS | Patent lapsed |